{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:12:49Z","timestamp":1771269169267,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"China Mega-Project for Infectious Diseases","award":["2017ZX10203202"],"award-info":[{"award-number":["2017ZX10203202"]}]},{"name":"China Mega-Project for Infectious Diseases","award":["2013ZX10002005"],"award-info":[{"award-number":["2013ZX10002005"]}]},{"name":"China Mega-Project for Innovative Drugs","award":["2016ZX09101065"],"award-info":[{"award-number":["2016ZX09101065"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clinre.2020.10.008","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T17:51:44Z","timestamp":1607104304000},"page":"101563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Combination of quantitative hepatitis B core antibody (qHBcAb) and aspartate aminotransferase (AST) can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy"],"prefix":"10.1016","volume":"45","author":[{"given":"Zhang","family":"Chi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0317-7536","authenticated-orcid":false,"given":"Wang","family":"Gui-Qiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10003","key":"10.1016\/j.clinre.2020.10.008_bib0005","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"issue":"9859","key":"10.1016\/j.clinre.2020.10.008_bib0010","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clinre.2020.10.008_bib0015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.clinre.2020.10.008_bib0020","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.clinre.2020.10.008_bib0025","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clinre.2020.10.008_bib0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2020.10.008_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.clinre.2020.10.008_bib0040","author":"World Health Organization"},{"issue":"4","key":"10.1016\/j.clinre.2020.10.008_bib0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1600-0676.1996.tb00741.x","article-title":"Variation between centers in technique and guidelines for liver biopsy","volume":"16","author":"Sue","year":"1996","journal-title":"Liver"},{"issue":"10","key":"10.1016\/j.clinre.2020.10.008_bib0050","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection","volume":"97","author":"Regev","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2020.10.008_bib0055","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2010.01.007","article-title":"Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia","volume":"52","author":"Nguyen","year":"2010","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2020.10.008_bib0060","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2010.01.014","article-title":"Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective","volume":"52","author":"Jaroszewicz","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2020.10.008_bib0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2893.2010.01270.x","article-title":"Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase","author":"Gui","year":"2010","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.clinre.2020.10.008_bib0070","article-title":"A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B","volume":"7","author":"Wk","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.clinre.2020.10.008_bib0075","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.clinre.2020.10.008_bib0080","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2893.2008.00989.x","article-title":"High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels","volume":"15","author":"Park","year":"2008","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.clinre.2020.10.008_bib0085","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.cgh.2007.01.005","article-title":"Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome","volume":"5","author":"Andreani","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2020.10.008_bib0090","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","article-title":"Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.clinre.2020.10.008_bib0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078672","article-title":"Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT","volume":"8","author":"Liao","year":"2013","journal-title":"PLoS One"},{"issue":"25","key":"10.1016\/j.clinre.2020.10.008_bib0100","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJM197806222982502","article-title":"Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen","volume":"298","author":"Hoofnagle","year":"1978","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clinre.2020.10.008_bib0105","doi-asserted-by":"crossref","first-page":"218","DOI":"10.7150\/thno.10636","article-title":"Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon","volume":"5","author":"Hou","year":"2015","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.clinre.2020.10.008_bib0110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/jvh.12626","article-title":"Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir","volume":"24","author":"Xu","year":"2017","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.clinre.2020.10.008_bib0115","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/gutjnl-2014-308546","article-title":"Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues","volume":"65","author":"Fan","year":"2016","journal-title":"Gut"},{"issue":"29","key":"10.1016\/j.clinre.2020.10.008_bib0120","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1097\/MD.0000000000000322","article-title":"Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study","volume":"93","author":"Jia","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.clinre.2020.10.008_bib0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cmi.2014.10.002","article-title":"Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection","volume":"21","author":"Song","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinre.2020.10.008_bib0130","unstructured":"World Health Organization WHO international standard: first international standard for anti\u2013hepatitis B core antigen. Available from: http:\/\/www.nibsc.ac.uk\/documents\/ifu\/95-522.pdf [accessed 10.11.08]."},{"issue":"6","key":"10.1016\/j.clinre.2020.10.008_bib0135","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2020.10.008_bib0140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","article-title":"Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.clinre.2020.10.008_bib0145","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.clinre.2020.10.008_bib0150","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"10.1016\/j.clinre.2020.10.008_bib0155","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2009.05.058","article-title":"Hepatitis B virus immunotolerant patients: need to differentiate patients with or without liver disease","volume":"137","author":"Kumar","year":"2009","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.clinre.2020.10.008_bib0160","first-page":"1566","article-title":"Hepatitis and leukemia: their relation to Australia antigen","volume":"44","author":"Blumberg","year":"1968","journal-title":"Bull N Y Acad Med"},{"issue":"1","key":"10.1016\/j.clinre.2020.10.008_bib0165","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1038\/s41598-017-03102-3","article-title":"Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.clinre.2020.10.008_bib0170","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B","volume":"143","author":"Kennedy","year":"2012","journal-title":"Gastroenterology"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740120303041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740120303041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:01Z","timestamp":1761895921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740120303041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2210740120303041"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2020.10.008","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of quantitative hepatitis B core antibody (qHBcAb) and aspartate aminotransferase (AST) can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2020.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101563"}}